Edition:
India

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.44USD
1:30am IST
Change (% chg)

$-0.03 (-2.04%)
Prev Close
$1.47
Open
$1.46
Day's High
$1.50
Day's Low
$1.40
Volume
1,595,165
Avg. Vol
267,206
52-wk High
$2.87
52-wk Low
$1.32

Latest Key Developments (Source: Significant Developments)

Great Point Partners Says Delivered Letter To Biocryst Pharma
Thursday, 21 Jun 2018 

June 20 (Reuters) - BioCryst Pharmaceuticals Inc ::GREAT POINT PARTNERS SAYS DELIVERED LETTER TO BIOCRYST PHARMACEUTICALS REAFFIRMING ITS OBJECTIONS TO PROPOSED MERGER OF BIOCRYST & IDERA PHARMACEUTICALS.  Full Article

Idera Pharmaceuticals Reports Results From Phase 2 Trial Of Imo-8400 In Dermatomyositis
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS REPORTS RESULTS FROM PHASE 2 TRIAL OF IMO-8400 IN DERMATOMYOSITIS.IDERA PHARMACEUTICALS INC - TRIAL DID NOT MEET ITS PRIMARY ENDPOINT.IDERA PHARMACEUTICALS INC - ANNOUNCED TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF IMO-8400 IN ADULT PATIENTS WITH DERMATOMYOSITIS.  Full Article

Biocryst Urges Stockholders To Vote "For" Merger Transaction With Idera
Tuesday, 5 Jun 2018 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC SAYS URGE STOCKHOLDERS TO VOTE "FOR" MERGER TRANSACTION WITH IDERA PHARMACEUTICALS.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Trial Collaboration And Supply Agreement With Bristol-Myers Squibb
Thursday, 24 May 2018 

May 24 (Reuters) - Bristol-Myers Squibb Co ::IDERA PHARMACEUTICALS SAYS EFFECTIVE MAY 18, 2018 ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL-MYERS SQUIBB.IDERA PHARMACEUTICALS - DEAL TO CLINICALLY EVALUATE COMBINATION OF CO'S TLR-9 AGONIST IMO-2125 WITH BMS'S THERAPY YERVOY.IDERA PHARMACEUTICALS INC - BMS GRANTED CO NON-EXCLUSIVE, NON-TRANSFERRABLE, ROYALTY-FREE LICENSE UNDER INTELLECTUAL PROPERTY TO USE YERVOY IN TRIAL.IDERA PHARMACEUTICALS - WILL SPONSOR, FUND, CONDUCT CO'S OPEN-LABEL, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH YERVOY.IDERA PHARMACEUTICALS INC - UPON TERMINATION OF DEAL, LICENSES GRANTED TO CO TO USE YERVOY(REG) IN TRIAL WILL TERMINATE.  Full Article

Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10
Wednesday, 9 May 2018 

May 9 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.10.Q1 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $107.5 MILLION COMPARED TO $112.6 MILLION AS OF DECEMBER 31, 2017.SEES EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND OPERATIONS INTO Q3 OF 2019.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation
Monday, 16 Apr 2018 

April 16 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA.IDERA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, PILLAR PARTNERS TO PROVIDE DIRECT FUNDING TO EXPAND CLINICAL RESEARCH OF IMO-2125.  Full Article

Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES.IDERA PHARMACEUTICALS INC - ‍MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.IDERA PHARMACEUTICALS INC - ROBERT INGRAM TO BE CHAIRMAN OF BOARD, VINCENT MILANO TO BE CEO OF COMBINED COMPANY.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF BIOCRYST COMMON STOCK WILL BE EXCHANGED FOR 0.50 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF IDERA COMMON STOCK WILL BE EXCHANGED FOR 0.20 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - ‍SIGNIFICANT STOCKHOLDER OF CO, BIOCRYST AGREED TO ENTER VOTING AND SUPPORT AGREEMENT AND HAS AGREED TO VOTE IN FAVOR OF DEAL​.IDERA PHARMACEUTICALS INC - AFTER DEAL BIOCRYST STOCKHOLDERS WILL OWN 51.6 PERCENT OF STOCK OF COMBINED COMPANY, CO'S STOCKHOLDERS TO OWN 48.4 PERCENT.IDERA PHARMACEUTICALS - COMBINED COMPANY, WHICH WILL BE RENAMED POST-CLOSING, WILL BE HEADQUARTERED AT CURRENT IDERA HEADQUARTERS.IDERA PHARMACEUTICALS INC - STOCK ISSUANCE IN MERGER IS EXPECTED TO BE TAX-FREE TO STOCKHOLDERS.  Full Article

Idera Pharmaceuticals Provides 2018 Update And Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS PROVIDES 2018 UPDATE AND OUTLOOK.IDERA PHARMACEUTICALS - ANTICIPATES CURRENT CASH POSITION CAPABLE OF FUNDING OPERATIONS INTO Q2 2019.  Full Article

U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Idera Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA.  Full Article

Idera Pharmaceuticals reports Q3 loss per share $0.10
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.10.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Idera Pharmaceuticals Inc - ‍ as of September 30, 2017, cash, cash equivalents and investments totaled $65.3 million​.Idera Pharmaceuticals Inc - ‍currently anticipate cash position capable of funding co's operations into Q2 of 2019​.  Full Article

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE